Search

Your search keyword '"Patel, Jatin"' showing total 656 results
Start Over Author "Patel, Jatin"
656 results on '"Patel, Jatin"'

14. Life Cycle Assessment of Electrocoagulation Pilot Unit for Dairy Wastewater Treatment

Author

Ankoliya, Dipak, Raninga, Milan, Patel, Dhaval, Mudgal, Varsha, Vallamsetty, Prashanthi, Mudgal, Anurag, Sinha, Manish Kumar, Patel, Vivek K., Patel, Jatin, Choksi, Himanshu, Dey, Prasanta, di Prisco, Marco, Series Editor, Chen, Sheng-Hong, Series Editor, Vayas, Ioannis, Series Editor, Kumar Shukla, Sanjay, Series Editor, Sharma, Anuj, Series Editor, Kumar, Nagesh, Series Editor, Wang, Chien Ming, Series Editor, Cui, Zhen-Dong, Series Editor, Lu, Xinzheng, Series Editor, Mudgal, Anurag, editor, Davies, Philip, editor, Kennedy, Maria, editor, Zaragoza, Guillermo, editor, and Park, Kiho, editor

Published
2024
Full Text
View/download PDF

15. Treatment of Domestic and Industrial Wastewater with Constructed Wetland—A Review

Author

Mudgal, Varsha, Raninga, Milan, Patel, Dhaval, Ankoliya, Dipak, Mudgal, Anurag, Patel, Jatin, Patel, Vivek, Srivastava, Rajeev, Khan, Suphiya, Kumar, Dinesh, di Prisco, Marco, Series Editor, Chen, Sheng-Hong, Series Editor, Vayas, Ioannis, Series Editor, Kumar Shukla, Sanjay, Series Editor, Sharma, Anuj, Series Editor, Kumar, Nagesh, Series Editor, Wang, Chien Ming, Series Editor, Cui, Zhen-Dong, Series Editor, Lu, Xinzheng, Series Editor, Mudgal, Anurag, editor, Davies, Philip, editor, Kennedy, Maria, editor, Zaragoza, Guillermo, editor, and Park, Kiho, editor

Published
2024
Full Text
View/download PDF

16. Batch Reverse Osmosis: Evolution from the Concept to the Technology

Author

Patel, Dhaval, Ankoliya, Dipak, Raninga, Milan, Mudgal, Anurag, Patel, Vivek, Patel, Jatin, Mudgal, Varsha, Choksi, Himanshu, di Prisco, Marco, Series Editor, Chen, Sheng-Hong, Series Editor, Vayas, Ioannis, Series Editor, Kumar Shukla, Sanjay, Series Editor, Sharma, Anuj, Series Editor, Kumar, Nagesh, Series Editor, Wang, Chien Ming, Series Editor, Cui, Zhen-Dong, Series Editor, Lu, Xinzheng, Series Editor, Mudgal, Anurag, editor, Davies, Philip, editor, Kennedy, Maria, editor, Zaragoza, Guillermo, editor, and Park, Kiho, editor

Published
2024
Full Text
View/download PDF

18. A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR).

Author

Patel, Jatin, Bass, Damon, Beishuizen, Albertus, Bocca Ruiz, Xavier, Boughanmi, Hatem, Cahn, Anthony, Colombo, Hugo, Criner, Gerard, Davy, Katherine, de-Miguel-Díez, Javier, Doreski, Pablo, Fernandes, Sofia, François, Bruno, Gupta, Anubha, Hanrott, Kate, Hatlen, Timothy, Inman, Dave, Isaacs, John, Jarvis, Emily, Kostina, Natalia, Kropotina, Tatiana, Lacherade, Jean-Claude, Lakshminarayanan, Divya, Martinez-Ayala, Pedro, McEvoy, Charlene, Meziani, Ferhat, Monchi, Mehran, Mukherjee, Sumanta, Muñoz-Bermúdez, Rosana, Neisen, Jessica, OShea, Ciara, Plantefeve, Gaëtan, Schifano, Lorrie, Schwab, Lee, Shahid, Zainab, Shirano, Michinori, Smith, Julia, Sprinz, Eduardo, Summers, Charlotte, Terzi, Nicolas, Tidswell, Mark, Trefilova, Yuliya, Williamson, Russell, Wyncoll, Duncan, and Layton, Mark

Subjects
Adult, Humans, COVID-19, Granulocyte-Macrophage Colony-Stimulating Factor, Antibodies, Monoclonal, Humanized, Respiratory Insufficiency, Double-Blind Method, Treatment Outcome
Abstract

BACKGROUND: Granulocyte-macrophage colony-stimulating factor (GM-CSF) and dysregulated myeloid cell responses are implicated in the pathophysiology and severity of COVID-19. METHODS: In this randomised, sequential, multicentre, placebo-controlled, double-blind study, adults aged 18-79 years (Part 1) or ≥70 years (Part 2) with severe COVID-19, respiratory failure and systemic inflammation (elevated C-reactive protein/ferritin) received a single intravenous infusion of otilimab 90 mg (human anti-GM-CSF monoclonal antibody) plus standard care (NCT04376684). The primary outcome was the proportion of patients alive and free of respiratory failure at Day 28. RESULTS: In Part 1 (n=806 randomised 1:1 otilimab:placebo), 71% of otilimab-treated patients were alive and free of respiratory failure at Day 28 versus 67% who received placebo; the model-adjusted difference of 5.3% was not statistically significant (95% CI -0.8-11.4%, p=0.09). A nominally significant model-adjusted difference of 19.1% (95% CI 5.2-33.1%, p=0.009) was observed in the predefined 70-79 years subgroup, but this was not confirmed in Part 2 (n=350 randomised) where the model-adjusted difference was 0.9% (95% CI -9.3-11.2%, p=0.86). Compared with placebo, otilimab resulted in lower serum concentrations of key inflammatory markers, including the putative pharmacodynamic biomarker CC chemokine ligand 17, indicative of GM-CSF pathway blockade. Adverse events were comparable between groups and consistent with severe COVID-19. CONCLUSIONS: There was no significant difference in the proportion of patients alive and free of respiratory failure at Day 28. However, despite the lack of clinical benefit, a reduction in inflammatory markers was observed with otilimab, in addition to an acceptable safety profile.

Published
2023

26. Study and Assessment of Solar Drying Configurations with Storage Incorporation

Author

Dudhiya, Milind, Parmar, Jaydip, Saxena, Rajat, Patel, Vivek, Patel, Jatin, Ghosh, Arindam, Series Editor, Chua, Daniel, Series Editor, de Souza, Flavio Leandro, Series Editor, Aktas, Oral Cenk, Series Editor, Han, Yafang, Series Editor, Gong, Jianghong, Series Editor, Jawaid, Mohammad, Series Editor, Mukherjee, Kalisadhan, editor, Layek, Rama Kanta, editor, and De, Debasis, editor

Published
2022
Full Text
View/download PDF

36. Upgradation of 82.6GHz ECRH system for SST-1 and Aditya-U

Author

Shukla Braj Kishore, Patel Jatin, Patel Harshida, Mistry Hardik, Purohit Dharmesh, Parmar K.G., Tai Evgeny, Soluyanova E., Khailov I.P., and Bakulin M.I.

Subjects
Physics, QC1-999
Abstract

In SST-1 and Aditya-U Tokamaks, two ECRH systems (42GHz-500kW and 82.6GHz-200k) are used to carry out various experiments related to ECRH assisted plasma start-up and heating at fundamental and second harmonic. The SST-1 tokamak is operated at 1.5T magnetic field and 42GHz ECRH system has been extensively for plasma start-up and heating. The 82.6GHz ECRH could not be used thoroughly due limitation in power as 200kW power is not enough for breakdown in SST-1 at second harmonic. The original 82.6GHz-200kW ECRH system is being upgraded in terms of ECRH power to carry out experiment at higher power. The 82.6GHz-200kW Gyrotron has been upgraded to 400kW power. The Gyrotron has been tested successfully at factory and delivers 400kW power at 48kV cathode voltage and draw around 20A cathode current, the efficiency of Gyrotron is around 42%. The 82.6GHz Gyrotron will be commissioned at IPR and the total ECRH power 0.9MW (0.5MW at 42GHz and 0.4MW at 82.6GHz) will facilitate to carry out ECR heating experiments simultaneously at fundamental and second harmonic. The paper presents the recent test results of 82.6GHz-400kW Gyrotron and discusses the experimental plan with upgraded ECRH system.

Published
2024
Full Text
View/download PDF

37. Experimental Investigation of Parabolic Trough Collector Using Cut Tube Receiver and Chronological Tracking

Author

Motwani, Karan, Patel, Jatin, Cavas-Martínez, Francisco, Series Editor, Chaari, Fakher, Series Editor, Gherardini, Francesco, Series Editor, Haddar, Mohamed, Series Editor, Ivanov, Vitalii, Series Editor, Kwon, Young W., Series Editor, Trojanowska, Justyna, Series Editor, Joshi, Preeti, editor, Gupta, Shakti S., editor, Shukla, Anoop Kumar, editor, and Gautam, Sachin Singh, editor

Published
2021
Full Text
View/download PDF

41. Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India

Author

Momin, Taufik, Kansagra, Kevinkumar, Patel, Hardik, Sharma, Sunil, Sharma, Bhumika, Patel, Jatin, Mittal, Ravindra, Sanmukhani, Jayesh, Maithal, Kapil, Dey, Ayan, Chandra, Harish, Rajanathan, Chozhavel TM, Pericherla, Hari PR, Kumar, Pawan, Narkhede, Anjali, and Parmar, Deven

Published
2021
Full Text
View/download PDF

45. Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study

Author

Buckley, Christopher D, Simón-Campos, Jesus A, Zhdan, Vyacheslav, Becker, Brandon, Davy, Katherine, Fisheleva, Elena, Gupta, Anubha, Hawkes, Carol, Inman, David, Layton, Mark, Mitchell, Nina, Patel, Jatin, Saurigny, Didier, Williamson, Russell, and Tak, Paul P

Published
2020
Full Text
View/download PDF

46. MRI of the joint and evaluation of the granulocyte–macrophage colony-stimulating factor–CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study

Author

Genovese, Mark C, Berkowitz, Mario, Conaghan, Philip G, Peterfy, Charles, Davy, Katherine, Fisheleva, Elena, Gupta, Anubha, Inman, David, Janiczek, Robert, Layton, Mark, Mitchell, Nina, Patel, Jatin, Roberts, Alexandra, Saurigny, Didier, Smith, Julia E, Williamson, Russell, and Tak, Paul P

Published
2020
Full Text
View/download PDF

49. ECRH experiments on Tokamaks SST-1 & Aditya-U and ECRH upgradation plan for SST-1

Author

Shukla Braj Kishore, Patel Jatin, Patel Harshida, Purohit Dharmesh, Mistry Hardik, and Parmar K.G.

Subjects
Physics, QC1-999
Abstract

A 42GHz-500kW ECRH system [1-6] is used to carry out various experiments related to plasma breakdown and ECR heating on tokamaks SST-1 and Aditya-U. The system has been upgraded with new anode modulator power supply to launch two ECRH pulses to carry out breakdown and heating simultaneously. In SST-1, ECRH system is used routinely for plasma breakdown at fundamental harmonic, approximately 150kW power is launched for 70ms to 150ms duration and consistent plasma start-up is achieved in SST-1. In the recent experiments, second EC pulse is also launched at the plasma flat-top to heat the plasma, some heating signatures are seen but more experiments will be carried out to confirm the plasma heating with ECRH. In Aditya-U tokamak, simultaneous plasma breakdown and heating experiments are carried out successfully [2]. In the first pulse around 100kW power in fundamental O-mode is launched for 70ms duration for the breakdown at low-loop voltage and around 150kW ECRH power for 50ms duration is launched in second EC pulse to heat the plasma. In case of Aditya-U, plasma heating is observed clearly as soft X-ray signal increases sharply with ECRH. In AdityaU tokamak, deuterium plasma experiments have been carried out and ECRH launched at the flat-top of deuterium plasma current. In deuterium plasma also ECR heating is observed as soft X-ray signal increases with ECH power. For SST-1, ECRH system is being upgraded with another 82.6GHz system, this system would be used to carry out plasma heating and start-up at second harmonic. The 82.6GHz system is already connected with the SST-1 tokamak, the old 82.6GHz-200kW Gyrotron will be upgraded to 400kW system to carry out effective heating experiments on SST-1 at higher ECRH power. The paper discusses the recent results of ECRH experiments carried out on tokamaks SST-1 & Aditya-U and presents the upgradation plan of EC system for SST-1.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results